Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 megan.manzari@myriad.com matt.scalo@myriad.com Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% Highlights • Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%). • Seco ...

Group 1 - Eurobio Scientific has completed the acquisition of the EndoPredict® genomic test from Myriad Genetics, finalizing the agreement initially announced on May 7, 2024 [1] - The acquisition includes the license to distribute the Prolaris® genomic test for prostate cancer, with combined annual revenues from these activities estimated at approximately €8 million [1] - The EBITDA levels from these new activities are expected to dilute the Group's performance in the short and medium term [1] Group 2 - Eurobio Scientific is a prominent player in specialty in vitro diagnostics, involved in research, manufacturing, and commercialization of diagnostic tests across various fields [2] - The company has a workforce of around 290 employees and operates four production units in France, Germany, the Netherlands, and the United States, along with several affiliates in various European countries [2] - Eurobio Scientific is publicly listed on the Euronext Growth market in Paris and is part of several indices, including Euronext European Rising Tech [3]

SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal ...

SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer Edition, which revealed that a majority (63%) of women do not know that there is an increased risk of breast cancer for women with dense breasts. The survey, now in its third year, focused on understanding the role of breast density and cancer risk among women ages 18+ in the U.S. Key survey ta ...

Myriad Genetics, Inc. (MYGN) recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD).The latest collaboration should help Myriad Genetics strengthen its market presence and broaden patients’ access to the benefits of MRD testing.About MRD TestMRD tests are blood-based diagnostic tools that enable clinicians to monitor therapeutic responses to cancer treatment more closely than with traditional cancer de ...

Myriad Genetics, Inc. (MYGN) recently secured a second foundational patent from the United States Patent and Trademark Office that bolsters its abilities to launch a tumor-informed, high-definition, molecular residual disease (MRD) assay. U.S. patent no. 12,024,749, entitled “Combinatorial DNA Screening,” covers the company’s breakthrough platform MRD technology, which enables highly sensitive and specific tumor-informed, sequencing-based MRD assays such as Precise MRD.The latest development reveals another ...

Core Viewpoint - Myriad Genetics has received a second patent for its tumor-informed, high-definition molecular residual disease (MRD) assay, enhancing its market position in precision medicine [1][3]. Patent Developments - The newly issued U.S. patent no. 12,024,749, titled "Combinatorial DNA Screening," focuses on Myriad's MRD technology, which detects circulating tumor DNA in patient fluid samples [1][2]. - Earlier this year, Myriad received a complementary patent for methods of preparing cell-free DNA, which also supports high sensitivity tumor-informed MRD assays [2]. Technology and Market Position - The combination of these patents positions Myriad to establish a proprietary MRD assay capable of detecting tumor DNA at lower levels than competitors, utilizing genome-scale sequencing technology [2]. - The company aims to leverage its existing technology and infrastructure to commercialize the Precise MRD assay, enhancing oncology care for patients [3]. Ongoing Research and Collaborations - Myriad is actively developing the Precise MRD assay through high-impact studies and collaborations with notable institutions, including Memorial Sloan Kettering and The University of Texas MD Anderson Cancer Center [3][4]. - Preliminary results from these collaborations are anticipated to be released in the fall [3]. Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [5].

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it’s a Great Place To Work – 27 percentage points higher than the average U.S. company. “It’s rare to work somewhere where everyone ...

Core Points - Myriad Genetics, Inc. has received the Great Place To Work Certification for the second consecutive year, with 84% of employees affirming it as a great workplace, which is 27 percentage points higher than the average U.S. company [1][2][3] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic tests that assess disease risk and guide treatment decisions [4] Employee Experience - Employees report a positive work environment, highlighting inclusivity, work/life balance, and a culture that values their opinions and preferences [2][3] - The Great Place To Work Certification reflects Myriad's commitment to fostering an open and collaborative work environment [3] Recognition and Impact - The Great Place To Work Certification is a significant achievement that indicates Myriad Genetics is among the top companies for employee experience, recognized globally for its high-trust workplace [5][6]

Core Insights - A nationwide survey indicates that 40% of Americans feel 'depressed and/or anxious' during the election season, highlighting the impact of politics on mental health [1][2] - The survey reveals that 38% of Americans report increased anxiety due to news and social media related to the election, while 35% feel overwhelmed by the amount of information [1][2] - Only 37% of Americans diagnosed with depression and/or anxiety are currently receiving mental health treatment, indicating a significant gap in care [2] Company Insights - Myriad Genetics, Inc. offers the GeneSight test, which provides clinicians with genetic information to help tailor medication for mental health conditions [5][6] - The GeneSight Psychotropic test is recognized as a leading pharmacogenomic test for over 60 medications commonly prescribed for mental health issues [5] - The GeneSight Mental Health Monitor is part of a series aimed at tracking the mental health effects of the election season, with further surveys planned for September and October [2][3] Industry Insights - The survey was conducted by ACUPOLL Precision Research, involving a representative sample of 1,000 U.S. adults, with a margin of error of +/- 3% [3] - The ongoing mental health crisis in the United States is underscored by the survey results, emphasizing the need for effective treatment methods combining medication and therapy [2] - The GeneSight test is positioned as a valuable tool for clinicians, especially during the heightened anxiety associated with the election period [8]